Demant report looks to future following two horrifying fiscal years

Following the 2019 hacker attack and the 2020 Covid-19 pandemic, hearing aid firm Demant once again looks to the future Tuesday morning as it presents its annual financial statement. Analysts' eyes are on the company's guidance.

Photo: Jens Dresling

Predominant emphasis will be placed on 2021 and expectations for the following year's development, when Demant hands in its yearly fiscal report Tuesday morning.

Following a couple of grim years starting with a hacker attack in September 2019, and following by the Covid-19 crisis last year, the ground has been laid for a more normalized 2021 for Demant, which is, however, still influenced by uncertainty caused by national lockdowns around the world.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs